Sign In
Buy DYAI
$1.05
-0.0200 (-1.87%)
At Close: Jul 31, 2026
DYAI Stock Increases Over 62% Intraday: Why It Happened
10:55am, Tuesday, 27'th Jul 2021
The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 62% during intraday trading. This is why it happened.
Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries
Dyadic's C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
08:30am, Monday, 28'th Jun 2021
JUPITER, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused
Dyadic' Stock Jumps On COVID-19 Vaccine Development Pact In India
09:25am, Wednesday, 26'th May 2021
Dyadic International Inc (NASDAQ: DYAI) has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate. The company says that the vaccine can potentially pro
DYAI Stock Price: Over 12% Increase Pre-Market Explanation
08:51am, Wednesday, 26'th May 2021
The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 12% pre-market. This is why it happened.
Dyadic to Present at Upcoming Events
08:30am, Monday, 24'th May 2021
JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its
Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2021 Results - Earnings Call Transcript
02:46am, Friday, 14'th May 2021
Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2021 Results - Earnings Call Transcript
DYAI's C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity
07:44am, Wednesday, 12'th May 2021
Dyadic International Inc (NASDAQ: DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn't simply a reproduction or tie-in to the b
Dyadic to Report First Quarter 2021 Financial Results
04:00pm, Thursday, 29'th Apr 2021
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, apply
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations t
Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript
12:28am, Wednesday, 31'st Mar 2021
Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript
Dyadic Reports 2020 Year End Results and Recent Company Progress
04:00pm, Tuesday, 30'th Mar 2021
Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption an
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
09:00pm, Monday, 22'nd Mar 2021
JUPITER, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused
DYAI Stock: Why Covid-19 Vaccine Play Dyadic Is Shooting Higher Today
04:03pm, Monday, 22'nd Mar 2021
Dyadic International is surging today after it announced a Covid vaccine partnership with Medytox, but that isn't the only bullish news for this small cap biotech stock. The post DYAI Stock: Why Covid
